By acquiring Santarus Inc., specialty firm Salix Pharmaceuticals Ltd. bolsters its gastrointestinal portfolio and increases the exposure of current and impending products to primary care.
While some analysts on a Salix earnings call on Nov. 7 criticized the deal’s sales multiple (6-7x), most were positive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?